Physician profile
Michael Gershberg
NPI 1679576029
$2,024.13
in general payments reported to CMS, 2019-2025
25 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $274 · 2021: $125 · 2022: $90.01 · 2023: $167 · 2024: $250 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $313.11 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.30 | 2019-2025 | Jardiance |
| Pfizer INC. | $282.58 | 2019-2025 | |
| Lilly USA, LLC | $188.14 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $163.32 | 2019-2025 | Farxiga, Flumist Quadrivalent |
| Sanofi Pasteur INC. | $103.54 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $85.88 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Abbott Laboratories | $69.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $59.93 | 2019-2021 | |
| Genentech USA, INC. | $54.23 | 2019-2020 | |
| Amgen INC. | $51.24 | 2019 | |
| Mylan Specialty L.P. | $49.64 | 2019-2020 | |
| Exact Sciences Corporation | $45.21 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $36.35 | 2021-2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $32.64 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.62 | 2019 | |
| Globus Medical, INC. | $22.32 | 2025 | Senza |
| Inspire Medical Systems, INC. | $21.77 | 2025 | Inspire |
| Bausch Health US, LLC | $21.32 | 2020 | |
| Astellas Pharma US INC | $20.21 | 2019 | |
| Amarin Pharma, INC. | $19.75 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.93 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2023 | Xifaxan |
| Collegium Pharmaceutical, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gershberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.